CL2012003274A1 - Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros. - Google Patents

Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.

Info

Publication number
CL2012003274A1
CL2012003274A1 CL2012003274A CL2012003274A CL2012003274A1 CL 2012003274 A1 CL2012003274 A1 CL 2012003274A1 CL 2012003274 A CL2012003274 A CL 2012003274A CL 2012003274 A CL2012003274 A CL 2012003274A CL 2012003274 A1 CL2012003274 A1 CL 2012003274A1
Authority
CL
Chile
Prior art keywords
bicyclo
cyclopentane
spiro
treatment
oab
Prior art date
Application number
CL2012003274A
Other languages
English (en)
Inventor
Srinivasa Rao Akireddy
Balwinder Singh Bhatti
Ronald Joseph Heemstra
Matt S Melvin
Jason Speake
Yunde Xiao
Daniel Yohannes
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CL2012003274A1 publication Critical patent/CL2012003274A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de espirociclos sustituidos, antagonistas no competitivos de receptores nicotínicos neuronales; composición farmacéutica; método de tratamiento o prevención; y su uso para el tratamiento o la prevención de una enfermedad o condición tal como IBS-D, OAB, adicción a la nicotina y dejar de fumar, entre otras.
CL2012003274A 2010-05-27 2012-11-23 Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros. CL2012003274A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34902710P 2010-05-27 2010-05-27
US37560610P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
CL2012003274A1 true CL2012003274A1 (es) 2013-05-24

Family

ID=44462072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003274A CL2012003274A1 (es) 2010-05-27 2012-11-23 Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.

Country Status (22)

Country Link
US (6) US8809397B2 (es)
EP (1) EP2576496B1 (es)
JP (2) JP5893610B2 (es)
KR (1) KR101856046B1 (es)
CN (2) CN102918021B (es)
AU (1) AU2011258553B2 (es)
BR (1) BR112012030004A2 (es)
CA (1) CA2799203C (es)
CL (1) CL2012003274A1 (es)
CO (1) CO6680603A2 (es)
ES (1) ES2623373T3 (es)
IL (2) IL223060A (es)
MX (1) MX337106B (es)
NZ (1) NZ603966A (es)
PE (1) PE20130775A1 (es)
PL (1) PL2576496T3 (es)
RU (2) RU2582339C2 (es)
SG (1) SG185643A1 (es)
TW (1) TW201200129A (es)
UY (1) UY33409A (es)
WO (2) WO2011149859A1 (es)
ZA (1) ZA201208836B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
EP2773609A4 (en) * 2011-11-03 2015-06-24 Targacept Inc NON-COMPETITIVE MODULATORS OF THE NICOTINE RECEPTOR
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
EP4267549A1 (en) 2020-12-23 2023-11-01 The Broad Institute Inc. Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931805A (en) * 1958-11-10 1960-04-05 Smith Kline French Lab Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines]
US3290215A (en) * 1963-10-29 1966-12-06 Du Pont Use of methanoindanamines as antiviral agents
US3317387A (en) * 1964-05-25 1967-05-02 Du Pont Method of reducing the severity of influenza virus infections
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2802486B2 (ja) 1995-11-30 1998-09-24 花王株式会社 トリシクロカルボン酸エステルおよびその製造法
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
CN2284883Y (zh) 1996-07-12 1998-06-24 陈智 纯滚活齿传动
AU740783B2 (en) * 1996-09-18 2001-11-15 Applied Genetics Incorporated Dermatics Pharmaceutical compositions and methods
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
EP1634498B1 (en) 1998-12-16 2008-09-03 University Of South Florida Exo-S-mecamylamine formulation
TW200306189A (en) * 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2003225456B2 (en) * 2002-04-18 2009-02-05 Astrazeneca Ab Furyl compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0413330A (pt) 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
KR20060125812A (ko) * 2003-12-22 2006-12-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
UA92327C2 (ru) * 2004-08-20 2010-10-25 Таргасепт, Инк. Применение n-арилдиазаспироциклических соединений для лечения зависимостей
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
WO2009039181A2 (en) 2007-09-17 2009-03-26 State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. Sulfonamide-based organocatalysts and method for their use
KR20100122508A (ko) * 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Also Published As

Publication number Publication date
CA2799203C (en) 2018-05-08
ES2623373T3 (es) 2017-07-11
TW201200129A (en) 2012-01-01
US10716770B2 (en) 2020-07-21
CN102918021B (zh) 2015-02-11
RU2582339C2 (ru) 2016-04-27
KR20130075748A (ko) 2013-07-05
ZA201208836B (en) 2013-07-31
CA2799203A1 (en) 2011-12-01
IL223060A0 (en) 2013-02-03
JP2016172717A (ja) 2016-09-29
CN102918021A (zh) 2013-02-06
WO2011149859A1 (en) 2011-12-01
UY33409A (es) 2013-01-03
WO2011149862A1 (en) 2011-12-01
RU2012157224A (ru) 2014-07-10
AU2011258553A1 (en) 2013-01-10
US8809397B2 (en) 2014-08-19
MX2012013618A (es) 2013-02-01
IL241743A0 (en) 2015-11-30
PE20130775A1 (es) 2013-07-21
US20140315877A1 (en) 2014-10-23
CO6680603A2 (es) 2013-05-31
SG185643A1 (en) 2012-12-28
EP2576496A1 (en) 2013-04-10
US10258582B2 (en) 2019-04-16
KR101856046B1 (ko) 2018-06-25
NZ603966A (en) 2015-03-27
US20180271806A1 (en) 2018-09-27
IL223060A (en) 2015-10-29
PL2576496T3 (pl) 2017-08-31
US9532974B2 (en) 2017-01-03
RU2016111390A (ru) 2017-10-04
JP5893610B2 (ja) 2016-03-23
CN104557568B (zh) 2017-04-12
BR112012030004A2 (pt) 2016-08-02
EP2576496B1 (en) 2017-03-08
JP2013528178A (ja) 2013-07-08
US20190254991A1 (en) 2019-08-22
MX337106B (es) 2016-02-12
CN104557568A (zh) 2015-04-29
US20170071878A1 (en) 2017-03-16
US20130203860A1 (en) 2013-08-08
US20160008323A1 (en) 2016-01-14
AU2011258553B2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
MX2013014978A (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
EA201590092A1 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
NI201500106A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno.
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2008003507A1 (es) Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
PE20150671A1 (es) Antagonistas del receptor de 5-ht3
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
CL2012003274A1 (es) Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.
WO2014008351A3 (en) Andrographis paniculata compositions and methods for treatment of addictions
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BRPI0807867A2 (pt) Derivado de indol ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um derivado de (indol-3-il) heterociclo, e, método de tratamento de dor
CL2007001795A1 (es) Compuestos derivados de 4-oxo-1,2,8-triaza-espiro[4.5] decano, que actuan como inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y uso de los compuestos en la prepararcion de medicamentos para tratar o prevenir arritmias cardiacas
UY33870A (es) Compuesto para el tratamiento de disfunción cognitiva en esquizofrenia, sus usos y composición que lo contiene
CL2007003110A1 (es) Compuestos derivados de ciclohexilamida, moduladores de los receptores de serotonina 5-ht2a y dopamina d3; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos cognitivos, adiccion a las drogas, depresi
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем